{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:31:10Z","timestamp":1790519470352,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R21MH0781003"],"award-info":[{"award-number":["R21MH0781003"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Narcolepsy is a chronic sleep disorder caused by a loss of hypocretin (hcrt) neurons in the hypothalamus. Cerebrospinal fluid (CSF) hcrt-1 measurement has been well established as a gold standard of narcolepsy diagnosis, although some portions of narcoleptic patients show normal hcrt-1 levels. We aimed to examine peptide degradation of hcrt-1 and its abnormality in the CSF of patients by using high performance liquid chromatography (HPLC) followed by radioimmunoassay (RIA). CSF was collected from healthy controls, narcoleptic patients of type 1 with hcrt-1 deficiency, type 1 with normal hcrt-1 level, and type 2 with normal hcrt-1 level. We found that the majority of hcrt-1 immunoreactivity in extracted CSF was derived from unauthentic hcrt-1 peaks, which are predicted to be inactive metabolites, and the intact hcrt-1 peptide was less than 10% of the gross amount, suggesting that the regular RIA for CSF hcrt-1 measures largely reflect the unauthentic hcrt-1-related metabolites rather than the intact one. As expected, all hcrt-1-related peaks were abolished in type 1 with hcrt-1 deficiency. Importantly, we also found that the sum of the authentic hcrt-1 peptide (peaks 3 and 4) significantly decreased in non-deficient type 1 and tended to decrease in type 2 narcoleptic patients although the levels with the regular RIA in non-extracted CSF was equivalent to healthy controls. Immunoreactivity with unauthentic hcrt-1 metabolites may masks the possible decline in authentic hcrt-1 level caused by the partial loss of hcrt neurons. Our findings may provide new insights into the degradation of the hcrt-1 peptide and the pathophysiology of narcolepsy.<\/jats:p>","DOI":"10.1038\/s41598-018-36942-8","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T06:05:12Z","timestamp":1548309912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy"],"prefix":"10.1038","volume":"9","author":[{"given":"Noriaki","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"36942_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","volume":"9","author":"S Nishino","year":"2005","unstructured":"Nishino, S. & Kanbayashi, T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system. Sleep Med Rev 9, 269\u2013310, https:\/\/doi.org\/10.1016\/j.smrv.2005.03.004 (2005).","journal-title":"Sleep Med Rev"},{"key":"36942_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474 (2000).","journal-title":"Neuron"},{"key":"36942_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6, 991\u2013997, https:\/\/doi.org\/10.1038\/79690 (2000).","journal-title":"Nat Med"},{"key":"36942_CR4","unstructured":"Medicine, A. A. o. S. International Classification of Sleep Disorders. 2nd edn, (2005)."},{"key":"36942_CR5","unstructured":"Medicine, A. A. o. S. International Classification of Sleep Disorders. 3rd edn, (2014)."},{"key":"36942_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59, 1553\u20131562 (2002).","journal-title":"Arch Neurol"},{"key":"36942_CR7","first-page":"565","volume":"37","author":"HY Kim","year":"2004","unstructured":"Kim, H. Y., Hong, E., Kim, J. I. & Lee, W. Solution structure of human orexin-A: Regulator of appetite and wakefulness. J Biochem Mol Biol 37, 565\u2013573 (2004).","journal-title":"J Biochem Mol Biol"},{"key":"36942_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","volume":"1200","author":"T Sakurai","year":"2010","unstructured":"Sakurai, T., Mieda, M. & Tsujino, N. The orexin system: roles in sleep\/wake regulation. Ann N Y Acad Sci 1200, 149\u2013161, https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05513.x (2010).","journal-title":"Ann N Y Acad Sci"},{"key":"36942_CR9","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18, 9996\u201310015 (1998).","journal-title":"J Neurosci"},{"key":"36942_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0006-8993(99)01336-0","volume":"827","author":"T Nambu","year":"1999","unstructured":"Nambu, T. et al. Distribution of orexin neurons in the adult rat brain. Brain Res 827, 243\u2013260 (1999).","journal-title":"Brain Res"},{"key":"36942_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1073\/pnas.96.2.748","volume":"96","author":"Y Date","year":"1999","unstructured":"Date, Y. et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 96, 748\u2013753 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"36942_CR12","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.5665\/sleep.2080","volume":"35","author":"O Andlauer","year":"2012","unstructured":"Andlauer, O. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35, 1247\u20131255F, https:\/\/doi.org\/10.5665\/sleep.2080 (2012).","journal-title":"Sleep"},{"key":"36942_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1086\/318799","volume":"68","author":"E Mignot","year":"2001","unstructured":"Mignot, E. et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68, 686\u2013699 (2001).","journal-title":"Am J Hum Genet"},{"key":"36942_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0165-5728(01)00333-2","volume":"117","author":"L Lin","year":"2001","unstructured":"Lin, L., Hungs, M. & Mignot, E. Narcolepsy and the HLA region. J Neuroimmunol 117, 9\u201320 (2001).","journal-title":"J Neuroimmunol"},{"key":"36942_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/sleep\/29.11.1429","volume":"29","author":"SC Hong","year":"2006","unstructured":"Hong, S. C. et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 29, 1429\u20131438 (2006).","journal-title":"Sleep"},{"key":"36942_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/sleep\/25.7.733","volume":"25","author":"LE Krahn","year":"2002","unstructured":"Krahn, L. E., Pankratz, V. S., Oliver, L., Boeve, B. F. & Silber, M. H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25, 733\u2013736 (2002).","journal-title":"Sleep"},{"key":"36942_CR17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/jnnp.74.12.1667","volume":"74","author":"Y Dauvilliers","year":"2003","unstructured":"Dauvilliers, Y. et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74, 1667\u20131673 (2003).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"36942_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/sleep\/30.8.969","volume":"30","author":"MS Heier","year":"2007","unstructured":"Heier, M. S. et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 30, 969\u2013973 (2007).","journal-title":"Sleep"},{"key":"36942_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1157\/13099970","volume":"128","author":"JE Martinez-Rodriguez","year":"2007","unstructured":"Martinez-Rodriguez, J. E., Iranzo, A., Casamitjana, R., Graus, F. & Santamaria, J. Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia. Med Clin (Barc) 128, 361\u2013364 (2007).","journal-title":"Med Clin (Barc)"},{"key":"36942_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/sleep\/33.2.169","volume":"33","author":"S Knudsen","year":"2010","unstructured":"Knudsen, S., Jennum, P. J., Alving, J., Sheikh, S. P. & Gammeltoft, S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 33, 169\u2013176 (2010).","journal-title":"Sleep"},{"key":"36942_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5664\/jcsm.2922","volume":"9","author":"LM Trotti","year":"2013","unstructured":"Trotti, L. M., Staab, B. A. & Rye, D. B. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med 9, 789\u2013795, https:\/\/doi.org\/10.5664\/jcsm.2922 (2013).","journal-title":"J Clin Sleep Med"},{"key":"36942_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.5665\/sleep.3756","volume":"37","author":"CR Baumann","year":"2014","unstructured":"Baumann, C. R. et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37, 1035\u20131042, https:\/\/doi.org\/10.5665\/sleep.3756 (2014).","journal-title":"Sleep"},{"key":"36942_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","volume":"32","author":"TC Thannickal","year":"2009","unstructured":"Thannickal, T. C., Nienhuis, R. & Siegel, J. M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 32, 993\u2013998 (2009).","journal-title":"Sleep"},{"key":"36942_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ana.1130","volume":"50","author":"S Nishino","year":"2001","unstructured":"Nishino, S. et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50, 381\u2013388 (2001).","journal-title":"Ann Neurol"},{"key":"36942_CR25","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"B Ripley","year":"2001","unstructured":"Ripley, B. et al. CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions. Neurology 57, 2253\u20132258 (2001).","journal-title":"Neurology"},{"key":"36942_CR26","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1126\/science.1067122","volume":"296","author":"JP Taylor","year":"2002","unstructured":"Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991\u20131995, https:\/\/doi.org\/10.1126\/science.1067122 (2002).","journal-title":"Science"},{"key":"36942_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/pr070501k","volume":"7","author":"A Zougman","year":"2008","unstructured":"Zougman, A. et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7, 386\u2013399, https:\/\/doi.org\/10.1021\/pr070501k (2008).","journal-title":"J Proteome Res"},{"key":"36942_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/psc.747","volume":"12","author":"T Takai","year":"2006","unstructured":"Takai, T. et al. Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor. J Pept Sci 12, 443\u2013454, https:\/\/doi.org\/10.1002\/psc.747 (2006).","journal-title":"J Pept Sci"},{"key":"36942_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1021\/jm030982t","volume":"47","author":"M Lang","year":"2004","unstructured":"Lang, M., Soll, R. M., Durrenberger, F., Dautzenberg, F. M. & Beck-Sickinger, A. G. Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J Med Chem 47, 1153\u20131160, https:\/\/doi.org\/10.1021\/jm030982t (2004).","journal-title":"J Med Chem"},{"key":"36942_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1124\/jpet.102.048025","volume":"305","author":"S Ammoun","year":"2003","unstructured":"Ammoun, S. et al. Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther 305, 507\u2013514, https:\/\/doi.org\/10.1124\/jpet.102.048025 (2003).","journal-title":"J Pharmacol Exp Ther"},{"key":"36942_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0960-894X(01)00043-9","volume":"11","author":"JG Darker","year":"2001","unstructured":"Darker, J. G. et al. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg Med Chem Lett 11, 737\u2013740 (2001).","journal-title":"Bioorg Med Chem Lett"},{"key":"36942_CR32","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1021\/ml400333a","volume":"4","author":"NA German","year":"2013","unstructured":"German, N. A., Decker, A. M., Gilmour, B. P., Thomas, B. F. & Zhang, Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 4, 1224\u20131227, https:\/\/doi.org\/10.1021\/ml400333a (2013).","journal-title":"ACS Med Chem Lett"},{"key":"36942_CR33","doi-asserted-by":"publisher","unstructured":"Ono, T., Kanbayashi, T., Yoshizawa, K., Nishino, S. & Shimizu, T. Measurement of cerebrospinal fluid orexin-A (hypocretin-1) by enzyme-linked immunosorbent assay: A comparison with radioimmunoassay. Psychiatry Clin Neurosci, https:\/\/doi.org\/10.1111\/pcn.12780 (2018).","DOI":"10.1111\/pcn.12780"},{"key":"36942_CR34","doi-asserted-by":"crossref","unstructured":"Nishino, S. & Sakurai, T. The orexin\/hypocretin system: physiology and pathophysiology. (Humana Press, 2005).","DOI":"10.1385\/1592599508"},{"key":"36942_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep25162","volume":"6","author":"C Hirtz","year":"2016","unstructured":"Hirtz, C. et al. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep 6, 25162, https:\/\/doi.org\/10.1038\/srep25162 (2016).","journal-title":"Sci Rep"},{"key":"36942_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1046\/j.0953-816x.2001.01725.x","volume":"14","author":"Y Yoshida","year":"2001","unstructured":"Yoshida, Y. et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14, 1075\u20131081 (2001).","journal-title":"Eur J Neurosci"},{"key":"36942_CR37","doi-asserted-by":"publisher","first-page":"e0151288","DOI":"10.1371\/journal.pone.0151288","volume":"11","author":"K Boddum","year":"2016","unstructured":"Boddum, K., Hansen, M. H., Jennum, P. J. & Kornum, B. R. Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Level Fluctuates with Season and Correlates with Day Length. PLoS One 11, e0151288, https:\/\/doi.org\/10.1371\/journal.pone.0151288 (2016).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36942-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T23:58:47Z","timestamp":1671235127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-36942-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["36942"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-36942-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"6 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"477"}}